ResearcherAlbany College of Pharmacy and Health SciencesNo recent work listed

Vandhana Muralidharan-Chari

ORCID-verified (high confidence, 0.95), identity_conf@1As of 9 November 2026

Matched on ORCID iD 0000-0001-7515-6585; OpenAlex author ID A5040987834. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2016: 1 paper

Papers 1

Microvesicle removal of anticancer drugs contributes to drug resistance in human pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.10395 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Mehdi Boroujerdi · 1 shared paper, 2016 · strength 0.06
- Paper Microvesicle removal of anticancer drugs contributes to drug resistance in human pancreatic cancer cells. DOI 10.18632/oncotarget.10395 ↗
Thangirala Sudha · 1 shared paper, 2016 · strength 0.06
- Paper Microvesicle removal of anticancer drugs contributes to drug resistance in human pancreatic cancer cells. DOI 10.18632/oncotarget.10395 ↗
Hamed Gilzad Kohan · 1 shared paper, 2016 · strength 0.06
- Paper Microvesicle removal of anticancer drugs contributes to drug resistance in human pancreatic cancer cells. DOI 10.18632/oncotarget.10395 ↗
Shaker A. Mousa · 1 shared paper, 2016 · strength 0.06
- Paper Microvesicle removal of anticancer drugs contributes to drug resistance in human pancreatic cancer cells. DOI 10.18632/oncotarget.10395 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.